Psoriasis is a multifactorial, chronic, auto- inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato-squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real-world setting for cancer patients with moderate-to-severe plaque psoriasis is lacking. Hence, we report the real-life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks.
Psoriatic patients with a history of cancer: a real-life experience with Apremilast treatment for 104 weeks / Bernardini, N., Skroza, N., Marchesiello, A., Mambrin, A., Proietti, I., Tolino, E., Maddalena, P., Marraffa, F., Rossi, G., Volpe, S., Potenza, C.. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 35:10(2022). [10.1111/dth.15306]
Psoriatic patients with a history of cancer: a real-life experience with Apremilast treatment for 104 weeks
Bernardini, Nicoletta
;Skroza, Nevena;Marchesiello, Anna;Mambrin, Alessandra;Proietti, Ilaria;Tolino, Ersilia;Maddalena, Patrizia;Marraffa, Federica;Volpe, Salvatore;Potenza, Concetta
2022
Abstract
Psoriasis is a multifactorial, chronic, auto- inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato-squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real-world setting for cancer patients with moderate-to-severe plaque psoriasis is lacking. Hence, we report the real-life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bernardini_Psoriatic-patients_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.04 MB
Formato
Adobe PDF
|
1.04 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
